What was CTI BioPharma Corp.’s price range in the past 12 months?
CTI BioPharma Corp. lowest share price was €0.65 and its highest was €0.65 in the past 12 months.
What is CTI BioPharma Corp.’s market cap?
Currently, no data Available
When is CTI BioPharma Corp.’s upcoming earnings report date?
CTI BioPharma Corp.’s upcoming earnings report date is Aug 03, 2023 which is 120 days ago.
How were CTI BioPharma Corp.’s earnings last quarter?
CTI BioPharma Corp. released its earnings results on May 11, 2023. The company reported -€0.091 earnings per share for the quarter, beating the consensus estimate of -€0.104 by €0.013.
CTI BioPharma Corp. does not currently pay dividends.
What is CTI BioPharma Corp.’s EPS estimate?
CTI BioPharma Corp.’s EPS estimate is -€0.07.
How many shares outstanding does CTI BioPharma Corp. have?
Currently, no data Available
What happened to CTI BioPharma Corp.’s price movement after its last earnings report?
CTI BioPharma Corp. reported an EPS of -€0.091 in its last earnings report, beating expectations of -€0.104. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CTI BioPharma Corp.?
Among the largest hedge funds holding CTI BioPharma Corp.’s share is Perceptive Advisors LLC. It holds CTI BioPharma Corp.’s shares valued at N/A.
CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.